NCT07758881尚未招募不适用
A Prospective, Single-arm, Interventional Study to Evaluate the Safety and Performance of the EIght Medical hyPeRthermia System IV 1.0, Used to Deliver Recirculating Hyperthermic Intravesical Chemotherapy (HIVEC) With Mitomycin C (MMC) for Treatment of Adult Patients With nOn-Muscle inVasive bladdER Cancer (NMIBC)
Eight Medical International BV2 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2027年1月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 30
- 试验地点
- 2
- 主要终点
- To assess the safety profile of the Eight Medical Hyperthermia System IV 1.0, used to deliver recirculating hyperthermic intravesical chemotherapy (HIVEC) with mitomycin C (MMC) in patients diagnosed with NMIBC.
研究概览
简要总结
The goal of this clinical trial is to evaluate the safety and performance of the Eight Medical Hyperthermia System IV 1.0 when used to deliver recirculating hyperthermic intravesical chemotherapy (HIVEC) with mitomycin C (MMC) in adult patients with non-muscle invasive bladder cancer (NMIBC).
The main questions it aims to answer are:
- Is the Eight Medical Hyperthermia System IV 1.0 safe when used to deliver HIVEC with MMC in adult patients with NMIBC?
- Does the Eight Medical Hyperthermia System IV 1.0 perform as intended by successfully delivering HIVEC with MMC?
Participants will:
- Receive HIVEC treatment with MMC using the Eight Medical Hyperthermia System IV 1.0 according to the study treatment schedule.
- Attend scheduled study visits for safety assessments, clinical evaluations, and follow-up.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •≥ 18 years of age at study entry.
- •Histologically confirmed intermediate-risk or high-risk NMIBC, as defined by the 2025 version of the European Association of Urology (EAU) guidelines.
- •ECOG Performance Status of 0-
- •Candidate for HIVEC according to clinical judgment and the device and medicinal product labeling/contra-indications.
- •The participant and investigator signed and dated the informed consent form prior to the treatment.
- •Available, willing, and with sufficient cognitive awareness to comply with the protocol or proposed follow-up visits.
排除标准
- •A small bladder capacity (<150 ml), based on site standard assessment and investigator judgment.
- •Active or uncontrolled Urinary Tract Infection (UTI), defined as clinical signs/symptoms and/or microbiological evidence requiring treatment per investigator judgment.
- •Positive urine culture prior to the instillation that indicates active infection not adequately treated or controlled.
- •Inability to hold urine for more than 1 hour.
- •Gross hematuria that precludes safe catheterization or intravesical therapy.
- •Severe bladder wall damage or other bladder pathology that increases the risk of complications or prevents safe instillation.
- •Non-controlled bladder overactivity that prevents completion of the planned dwell time.
- •Urethral strictures or other anatomical/functional conditions that complicate or prevent safe catheterization.
- •Known vesico-ureteral reflux that increases risk with intravesical chemotherapy.
- •Inability to remain in the supine position for at least 60 minutes.
- •Known allergy or hypersensitivity to Mitomycin C.
- •Current or history of clinically significant hematologic disorder that may increase risk of bleeding, infection, or systemic toxicity, or confound safety assessment.
- •Autoimmune disease, systemic inflammatory disease or other medical conditions that will likely affect study outcomes or participant safety.
- •Tumor tissue in the bladder containing <50% urothelial cancer.
- •(A history of) muscle-invasive bladder cancer (≥ T2) or metastatic disease.
- •Participants with a history of other active malignancies are excluded, except in cases where the malignancy is considered adequately treated, clinically stable, and unlikely to interfere with the safety or efficacy evaluation of the investigational treatment.
- •Prior HIVEC or intravesical chemotherapy is permitted, provided a minimum washout period of 6 months has elapsed since the last instillation and there are no ongoing clinically significant adverse events from prior treatments.
- •Participants with concurrent chemotherapy.
- •Participant is pregnant, plans to become pregnant, or is lactating.
- •Male participants who are not vasectomized, and are unwilling or unable to use a highly effective method of contraception.
- •Participant is enrolled in another study or there is concurrent participation or participation within 30 days in any other clinical trial with an investigational product.
结局指标
主要结局
To assess the safety profile of the Eight Medical Hyperthermia System IV 1.0, used to deliver recirculating hyperthermic intravesical chemotherapy (HIVEC) with mitomycin C (MMC) in patients diagnosed with NMIBC.
时间窗: Visit 1 (week 1), visit 2 (week 2), visit 3 (week 3), visit 4 (week 4), visit 5 (week 5), visit 6 (week 6), visit 7 (week 10), visit 8 (week 14), visit 9 (week 18), visit 10 (week 22), visit 11 (week 26), visit 12 (week 30), study exit visit (week 34)
Safety will be assessed by documenting all peri- and post-treatment (serious) adverse events, from the treatment onwards up to 30 days post-treatment (defined as the date of last intravesical instillation). This will include assessment of the frequency, severity, and nature of the (serious) adverse events and the treatment received.
次要结局
- To evaluate the performance of the Eight Medical Hyperthermia System IV 1.0, used to deliver recirculating HIVEC with MMC in patients diagnosed with NMIBC.(Visit 1 (week 1), visit 2 (week 2), visit 3 (week 3), visit 4 (week 4), visit 5 (week 5), visit 6 (week 6), visit 7 (week 10), visit 8 (week 14), visit 9 (week 18), visit 10 (week 22), visit 11 (week 26), visit 12 (week 30).)
- To evaluate the usability of the Eight Medical Hyperthermia System IV 1.0, used to deliver recirculating HIVEC with MMC in patients diagnosed with NMIBC.(8 months)
- To evaluate the short-term clinical effectiveness of the treatment administered by the Eight Medical Hyperthermia System IV 1.0.(3 months)
- To evaluate the short-term clinical effectiveness of the treatment administered by the Eight Medical Hyperthermia System IV 1.0.(6 months)
- To evaluate the short-term clinical effectiveness of the treatment administered by the Eight Medical Hyperthermia System IV 1.0.(8 months)
- To evaluate the Quality of Life of study participants treated with the Eight Medical Hyperthermia System IV 1.0.(During treatment visit 1 (week 1))
- To evaluate the Quality of Life of study participants treated with the Eight Medical Hyperthermia System IV 1.0.(During treatment visit 6 (week 6))
- To evaluate the Quality of Life of study participants treated with the EightMedical Hyperthermia System IV 1.0.(During treatment visit 6 (week 6))
- To evaluate the Quality of Life of study participants treated with the Eight Medical Hyperthermia System IV 1.0.(During treatment visit 8 (3 months after first instillation))
- To evaluate the Quality of Life of study participants treated with the Eight Medical Hyperthermia System IV 1.0.(During treatment visit 11 (6 months after first instillation))
研究者
研究点 (2)
Loading locations...
相似试验
招募中
2/3 期
Study of HSSH-062501 Tablets in People with Mild to Moderate Chronic Joint PainCTRI/2025/11/097144Himalaya Wellness Company300
尚未招募
2 期
A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICCIntrahepatic CholangiocarcinomaNCT07432568Tianjin Medical University Cancer Institute and Hospital30
招募中
不适用
40 Hz Flickering for Insomnia in Parkinson's DiseaseInsomniaParkinson DiseaseInsomniaNCT07323121Jiangsu Province Nanjing Brain Hospital30
尚未招募
不适用
A Study to Check the Safety and Benefits of Tatkal Capsules in Adult Men with Erectile Dysfunction.CTRI/2026/04/108451Renovision Exports Pvt. Ltd50
招募中
2 期
Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System LymphomaNCT07416890Zhejiang Cancer Hospital24